7. Approaches to glycemic treatment

Diabetes Care

Volumn 39, Issue , 2016, Pages S52-S59

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ALOGLIPTIN; BROMOCRIPTINE; CANAGLIFLOZIN; COLESEVELAM; DAPAGLIFLOZIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLIBENCLAMIDE; GLIPIZIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; HEMOGLOBIN A1C; INSULIN; LINAGLIPTIN; LIRAGLUTIDE; METFORMIN; MIGLITOL; NATEGLINIDE; PIOGLITAZONE; PRAMLINTIDE; REPAGLINIDE; ROSIGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA; UNINDEXED DRUG; VILDAGLIPTIN;

ABDOMINAL CRAMP; ACUTE PANCREATITIS; ANGIONEUROTIC EDEMA; ARTICLE; BARIATRIC SURGERY; BLOOD GLUCOSE MONITORING; CONSTIPATION; CONTINUOUS INFUSION; COST EFFECTIVENESS ANALYSIS; CYANOCOBALAMIN DEFICIENCY; DIABETIC KETOACIDOSIS; DIARRHEA; DIZZINESS; EDEMA; FAINTNESS; FAMILY COUNSELING; FATIGUE; FLATULENCE; FRACTURE; GLYCEMIC CONTROL; HEART FAILURE; HUMAN; HYPERTRIGLYCERIDEMIA; HYPOGLYCEMIA; HYPOTENSION; INDIVIDUALIZATION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN PUMP; KETOACIDOSIS; LIFESTYLE MODIFICATION; LOW CARBOHYDRATE DIET; LOW FAT DIET; META ANALYSIS (TOPIC); NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PANCREAS ISLET TRANSPLANTATION; PATIENT ATTITUDE; PATIENT CARE; PATIENT SELECTION; PHYSICAL ACTIVITY; POLYURIA; POSTPRANDIAL STATE; PYELONEPHRITIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHINITIS; SIDE EFFECT; SKIN DISEASE; SYSTEMATIC REVIEW (TOPIC); TACHYCARDIA; THYROID TUMOR; TREATMENT OUTCOME; URINARY TRACT INFECTION; UROGENITAL TRACT INFECTION; UROSEPSIS; URTICARIA; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 84960189946     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc16-S010     Document Type: Article

References (36)

1. Wallia A, Molitch ME. Insulin therapy for type 2 diabetes mellitus. JAMA 2014;311:2315-2325
2. Yeh H-C, Brown TT, Maruthur N, et al. Comparative effectiveness and safety of methods of insulin delivery and glucose monitoring for diabetes mellitus: a systematic review and metaanalysis. Ann Intern Med 2012;157:336-347
3. Bergenstal RM, Klonoff DC, Garg SK, et al.; ASPIRE In-Home Study Group. Thresholdbased insulin-pump interruption for reduction of hypoglycemia. N Engl J Med 2013;369:224-232
4. Wood JR, Miller KM, Maahs DM, et al.; T1D Exchange Clinic Network. Most youth with type 1 diabetes in the T1D Exchange clinic registry do not meet American Diabetes Association or International Society for Pediatric and Adolescent Diabetes clinical guidelines. Diabetes Care 2013;36:2035-2037
5. Kmietowicz Z. Insulin pumps improve control and reduce complications in children with type 1 diabetes. BMJ 2013;347:f5154
6. Phillip M, Battelino T, Atlas E, et al. Nocturnal glucose control with an artificial pancreas at a diabetes camp. N Engl J Med 2013;368:824-833
7. Wolpert HA, Atakov-Castillo A, Smith SA, Steil GM. Dietary fat acutely increases glucose concentrations and insulin requirements in patients with type 1 diabetes: implications for carbohydrate-based bolus dose calculation and intensive diabetes management. Diabetes Care 2013;36:810-816
8. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulindependent diabetes mellitus. N Engl J Med 1993;329:977-986
9. Nathan DM, Cleary PA, Backlund J-Y C, et al.; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643-2653
10. De Witt DE, Hirsch IB. Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: scientific review. JAMA 2003;289:2254-2264
11. Rosenstock J, Dailey G, Massi-Benedetti M, Fritsche A, Lin Z, Salzman A. Reduced hypoglycemia riskwith insulin glargine: ameta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care 2005;28:950-955
12. MannKind Corporation. Briefing Document: Endocrinologic and Metabolic Drug Advisory Committee. AFREZZA (insulin human [rDNA origin]) inhalation powder. An ultra-rapid acting insulin treatment to improve glycemic control in adult patients with diabetes mellitus [Internet], 2014. Available from http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisory Committee/UCM390865.pdf. Accessed 6 November 2015
13. American Diabetes Association. Pancreas and islet transplantation in type 1 diabetes. Diabetes Care 2006;29:935
14. Vella S, Buetow L, Royle P, Livingstone S, Colhoun HM, Petrie JR. The use of metformin in type 1 diabetes: a systematic review of efficacy. Diabetologia 2010;53:809-820
15. Chiang JL, Kirkman MS, Laffel LM, Peters AL; Type 1 Diabetes Sourcebook Authors. Type 1 diabetes through the life span: a position statement of the American Diabetes Association. Diabetes Care 2014;37:2034-2054
16. U. S. Food and Drug Administration. SGLT2 inhibitors: drug safety communication - labels to include warnings about too much acid in the blood and serious urinary tract infections [Internet], 4 December 2015. Available from http://www.fda.gov/safety/medwatch/safetyinformation/safetyalertsforhumanmedical products/ucm475553.htm. Accessed 7 December 2015
17. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015;38:140-149
18. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-1589
19. Inzucchi SE, Lipska KJ, Mayo H, Bailey CJ, McGuire DK. Metformin in patients with type 2 diabetes and kidney disease: a systematic review. JAMA 2014;312:2668-2675
20. Bennett WL, Maruthur NM, Singh S, et al. Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med 2011;154:602-613
21. Nathan DM, Buse JB, Kahn SE, et al.; GRADE Study Research Group. Rationale and design of the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE). Diabetes Care 2013;36:2254-2261
22. Green JB, Bethel MA, Armstrong PW, et al.; TECOS Study Group. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015;373:232-242
23. Vijan S, Sussman JB, Yudkin JS, Hayward RA. Effect of patients' risks and preferences on health gains with plasma glucose level lowering in type 2 diabetes mellitus. JAMA Intern Med 2014;174:1227-1234
24. Institute for Clinical and Economic Review. Controversies in the management of patients with type 2 diabetes [Internet], 2014. Available from http://cepac.icer-review.org/wp-content/uploads/2014/08/CEPAC-T2D-Final-Report-December-22.pdf. Accessed 6 November 2015
25. Blonde L, Merilainen M, Karwe V, Raskin P; TITRATE Study Group. Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targetsdthe TITRATE study. Diabetes Obes Metab 2009;11:623-631
26. Tricco AC, Ashoor HM, Soobiah C, et al. Safety, effectiveness, and cost of long-acting versus intermediate-acting insulin for type 1 diabetes: protocol for a systematic review and network meta-analysis. Syst Rev 2013;2:73
27. Eng C, Kramer CK, Zinman B, Retnakaran R. Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis. Lancet 2014;384:2228-2234
28. Reznik Y, Cohen O, Aronson R, et al.; OpT2mise Study Group. Insulin pump treatment compared with multiple daily injections for treatment of type 2 diabetes (OpT2mise): a randomised open-label controlled trial. Lancet 2014;384:1265-1272
29. Johnson SL, McEwen LN, Newton CA, et al. The impact of continuous subcutaneous insulin infusion and multiple daily injections of insulin on glucose variability in older adults with type 2 diabetes. J Diabetes Complications 2011;25:211-215
30. Herman WH, Ilag LL, Johnson SL, et al. A clinical trial of continuous subcutaneous insulin infusion versus multiple daily injections in older adults with type 2 diabetes. Diabetes Care 2005;28:1568-1573
31. Zinman B, Wanner C, Lachin JM, et al.; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 17 September 2015 [Epub ahead of print]. DOI: 10.1056/NEJMoa1504720
32. Dormandy JA, Charbonnel B, Eckland DJA, et al.; PROactive Investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial InmacroVascular Events): a randomised controlled trial. Lancet 2005;366:1279-1289
33. Chiasson J-L, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M; STOP-NIDDM Trial Research Group. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDMrandomised trial. Lancet 2002;359:2072-2077
34. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853
35. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-865
36. Gaziano JM, Cincotta AH, O'Connor CM, et al. Randomized clinical trial of quickrelease bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes. Diabetes Care 2010;33:1503-1508